OKYO Pharma Limited ("OKYO" or the "Company") to File IND in Q3 2022 for OK-101 to treat Dry Eye Disease ("DED") and to go directly to a Phase 2 Human Clinical Efficacy Trial in DED Patients with a planned start date in Q4 2022 on an accelerated basis
December 06, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), the biotechnology company focused on the discovery and development of novel molecules to treat inflammatory...
OKYO Pharma Limited: Directorate Change
December 01, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that Bernard Denoyer has been appointed as a non-executive director of the Company with...
OKYO Pharma Limited ("OKYO" or the "Company") - Result of Annual General Meeting
September 27, 2021 07:17 ET
|
OKYO Pharma LTD
LONDON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye...
OKYO Pharma Limited ("OKYO" or the "Company") - Notice of Annual General Meeting
September 09, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021
August 02, 2021 06:57 ET
|
OKYO Pharma LTD
LONDON, Aug. 02, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (the “Company”) is pleased to announce its final audited results for the year ended 31 March 2021. Summary of OKYO-101 studies during...
("OKYO" or the "Company") - OKYO Pharma Retains Ora Inc. to Perform Regulatory Development of OK-101 for Dry Eye Indications
June 29, 2021 08:14 ET
|
OKYO Pharma LTD
LONDON and BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
("OKYO" or the "Company") - OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain
April 28, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON and BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO announces appointment of Dr Rajkumar Patil as Chief Scientific Officer
March 29, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, March 29, 2021 (GLOBE NEWSWIRE) -- OKYO (LSE: OKYO; OTCQB: EMMLF), the life sciences and biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited ("OKYO" or the "Company") - Issue of Equity
March 01, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, March 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that it has issued 250,000 ordinary shares of no par value ("Ordinary Shares"), credited as...
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
February 23, 2021 02:00 ET
|
OKYO Pharma LTD
LONDON, Feb. 23, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company"), a biotechnology company focused on the development of novel drugs to treat inflammatory eye diseases and...